AU2001240001A1 - Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same - Google Patents
Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the sameInfo
- Publication number
- AU2001240001A1 AU2001240001A1 AU2001240001A AU4000101A AU2001240001A1 AU 2001240001 A1 AU2001240001 A1 AU 2001240001A1 AU 2001240001 A AU2001240001 A AU 2001240001A AU 4000101 A AU4000101 A AU 4000101A AU 2001240001 A1 AU2001240001 A1 AU 2001240001A1
- Authority
- AU
- Australia
- Prior art keywords
- tegafur
- oxaliplatin
- uracil
- administration
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 title 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title 1
- 235000008191 folinic acid Nutrition 0.000 title 1
- 239000011672 folinic acid Substances 0.000 title 1
- 229960001691 leucovorin Drugs 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 title 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title 1
- 229960001756 oxaliplatin Drugs 0.000 title 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title 1
- 229960001674 tegafur Drugs 0.000 title 1
- 229940035893 uracil Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18784200P | 2000-03-08 | 2000-03-08 | |
| US60187842 | 2000-03-08 | ||
| US23114700P | 2000-09-08 | 2000-09-08 | |
| US60231147 | 2000-09-08 | ||
| PCT/US2001/006730 WO2001066102A2 (fr) | 2000-03-08 | 2001-03-01 | Forme posologique orale d'administration de la combinaison de tegafur, uracile, acide folique et oxaliplatine et procede d'utilisation correspondant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001240001A1 true AU2001240001A1 (en) | 2001-09-17 |
Family
ID=26883457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001240001A Abandoned AU2001240001A1 (en) | 2000-03-08 | 2001-03-01 | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6602870B2 (fr) |
| AR (1) | AR027624A1 (fr) |
| AU (1) | AU2001240001A1 (fr) |
| PE (1) | PE20020769A1 (fr) |
| WO (1) | WO2001066102A2 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476068B1 (en) | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
| FR2834641B1 (fr) * | 2002-01-14 | 2005-04-22 | Ct Regional De Lutte Contre Le | Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium |
| EP1604991B1 (fr) * | 2003-03-14 | 2008-09-17 | Taiho Pharmaceutical Co., Ltd. | Potentialisateur de l'effet antitumoral et agent antitumoral |
| KR100844477B1 (ko) * | 2004-06-09 | 2008-07-07 | 다이호야쿠힌고교 가부시키가이샤 | 항종양 효과 증강제, 항종양제 및 암 치료 방법 |
| SI1757283T1 (sl) * | 2004-06-09 | 2013-01-31 | Taiho Pharmaceutical Co., Ltd. | Ojačevalec protitumorskega učinka, protitumorsko sredstvo in postopek terapije za rak |
| US20080081301A1 (en) * | 2006-10-03 | 2008-04-03 | Hannum Mark C | Low NOx combustion |
| ATE530188T1 (de) * | 2007-03-02 | 2011-11-15 | Univ Wollongong | Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs |
| US8007470B2 (en) * | 2007-07-10 | 2011-08-30 | Cook Medical Technologies Llc | Minimally invasive medical device and method for delivery of therapeutic or diagnostic agents into a vessel wall |
| AU2008356312B2 (en) * | 2008-05-12 | 2015-04-09 | Shizuoka Prefecture | Antitumor agent, kit, and method for treating cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328229A (en) | 1978-03-29 | 1982-05-04 | Taiho Pharmaceutical Company Limited | Anti-cancer composition for delivering 5-fluorouracil to cancer tissues |
| US5534513A (en) | 1991-09-05 | 1996-07-09 | Taiho Pharmaceutical Company, Ltd. | Antitumor potentiator and antitumor composition |
-
2001
- 2001-03-01 WO PCT/US2001/006730 patent/WO2001066102A2/fr active Application Filing
- 2001-03-01 AU AU2001240001A patent/AU2001240001A1/en not_active Abandoned
- 2001-03-07 US US09/800,675 patent/US6602870B2/en not_active Expired - Fee Related
- 2001-03-08 AR ARP010101100A patent/AR027624A1/es unknown
- 2001-06-12 PE PE2001000553A patent/PE20020769A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6602870B2 (en) | 2003-08-05 |
| WO2001066102A3 (fr) | 2001-12-20 |
| WO2001066102A2 (fr) | 2001-09-13 |
| PE20020769A1 (es) | 2002-09-06 |
| US20020045632A1 (en) | 2002-04-18 |
| AR027624A1 (es) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161431A0 (en) | beta-PHENYL-alpha-OXYSUBSTITUTED PROPIONIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| HUP0202795A3 (en) | Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use | |
| HUP0301722A3 (en) | Pyrimidine derivatives, pharmaceutical compositions containing them and their use | |
| AU2002219174A1 (en) | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof | |
| HUP0401346A3 (en) | Hiv inhibiting pyrimidines derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0201122A3 (en) | Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them | |
| PL396568A1 (pl) | Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny | |
| HUP0105114A3 (en) | Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation | |
| HUP0401083A3 (en) | 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds | |
| AU2001284021A1 (en) | Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof | |
| IL138969A0 (en) | Anthranilic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| HK1052510A1 (en) | Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines. | |
| PL363967A1 (en) | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin | |
| HUP0203385A3 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| ZA200109602B (en) | Purine derivatives, preparation method and pharmaceutical compositions containing same. | |
| AU2001240001A1 (en) | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same | |
| AU2001234107A1 (en) | Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | |
| EP1490358A4 (fr) | Derives de 6-(anilino-4-substitue)pyrimidine, procede de preparation de ces derives et composition pharmaceutique antivirale les contenant | |
| HUP0303045A3 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| IL148573A0 (en) | New pyrimidine -2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | |
| AU2001296746A1 (en) | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same | |
| AU2002325614A1 (en) | Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances | |
| HUP0303953A3 (en) | Method for preparation of pharmaceutical composition for treating tumors by using tegafur, uracil, folinic acid, and cyclophospamide | |
| AU2002213119A1 (en) | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same | |
| IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof |